This study investigates the use of Sintilimab combined with chemotherapy and radiotherapy in patients with inoperable pancreatic cancer. The purpose is to explore if this combination can improve outcomes for individuals with this condition.

Researchers are evaluating the safety and effectiveness of combining Sintilimab, a type of immunotherapy, with chemotherapy and radiotherapy. This study focuses on understanding how these treatments work together to potentially provide better results in managing pancreatic cancer.

• Who can participate: Participants must have locally advanced pancreatic cancer that cannot be surgically removed and should not have received any prior systemic anti-tumor therapy. They must have a life expectancy of more than 3 months, with other health criteria also applying.
• Study details: Participants in the study will receive Sintilimab along with chemotherapy and radiotherapy. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.